Reporting Manager
Trails Edge Capital Partners, LP
Symbol
IKT
Shares outstanding
120,494,078 shares
Disclosed Ownership
6,145,198 shares
Ownership
5.1%
Form type
SCHEDULE 13G
Filing time
31 Dec 2025, 17:00:18 UTC
Date of event
23 Dec 2025

Sponsored

Quoteable Key Fact

"Trails Edge Capital Partners, LP disclosed 5.1% ownership in Inhibikase Therapeutics, Inc. Common Stock, $0.001 par value (IKT) on 23 Dec 2025."

Quick Takeaways

  • Trails Edge Capital Partners, LP filed SCHEDULE 13G for Inhibikase Therapeutics, Inc. Common Stock, $0.001 par value (IKT).
  • Disclosed ownership: 5.1%.
  • Date of event: 23 Dec 2025.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 31 Dec 2025, 17:00.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Official SEC Source

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (3)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Trails Edge Capital Partners, LP 5.1% 6,145,198 6,145,198 0 : Trails Edge Capital Partners, LLC, GP of Trails Edge Capital Partners, LP /s/ Ortav Yehudai Ortav Yehudai / Chief Investment Officer of Trails Edge Capital Partners, LLC
Trails Edge Biotechnology Master Fund, LP 5.1% 6,145,198 6,145,198 0 Trails Edge GP, LLC, GP of Trails Edge Biotechnology Fund GP, LP, GP of Trails Edge Biotechnology Master Fund, LP /s/ Ortav Yehudai Ortav Yehudai / Chief Investment Officer of Trails Edge GP, LLC
Ortav Yehudai 5.1% 6,145,198 6,145,198 0 /s/ Ortav Yehudai Ortav Yehudai / Individual